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Abstract. 
Background: The intent of this study was to explore the treatment efficacy of erlotinib, 
pemetrexed or docetaxel in individual patients with tumor EGFR wild-type pulmonary 
adenocarcinoma who failed previous chemotherapy. 
Methods: We retrospectively reviewed the clinical data of our EGFR wild-type pulmonary 
adenocarcinoma patients who had disease progression after first-line chemotherapy and also 
had received erlotinib and pemetrexed or docetaxel treatment in our institution any time from 
July 2009 to June 2012.  
Results: Forty-one patients were identified and enrolled into the present study; all of them 
received erlotinib treatment. Thirty-five patients received additional pemetrexed treatment and 
30 patients received additional docetaxel treatment, either preceding or following failure of 
erlotinib treatment. Erlotinib was used more frequently as a second-line treatment in 27 of 41 
(65.9%) patients, followed by pemetrexed, which was used more frequently in the third-line 
setting for 21 of 35 (60%) patients. Docetaxel was typically used as the fourth-line treatment 
for 14 of 30 (46.7%) patients (all p < 0.01 when comparing different treatment agents). There 
was no difference in the tumor response rate between erlotinib (19.5%), pemetrexed (17.1%), 
and docetaxel (6.7%) (p = 0.301). For all patients, the median progression-free survival (PFS) 
was 10.9 weeks, 13.3 weeks, and 8.3 weeks when using erlotinib, pemetrexed, and docetaxel, 
respectively, as ≥ second-line treatment (p = 0.0261). No significant difference in PFS was 
found for individual agents when used in an earlier or later line of salvage therapy.  
Conclusions: This retrospective study of tumor EGFR wild-type pulmonary adenocarcinoma 
patients showed that erlotinib, pemetrexed, or docetaxel, individually, provided effective sal-
vage therapy when patients had disease progression subsequent to first-line chemotherapy. 
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中文摘要 
  本研究之目的是探討野生型上皮細胞生長因素接收器之肺腺癌患者於第一線化學治
療失敗之後，使用 erlotinib，pemetrexed，或 docetaxel 的治療效果差異。我們於民國 98
年 7 月至 101 年 6 月期間，收集了 41 個患者作分析，所有人於病程中皆有使用到 erlotinib，
35人有使用pemetrexed，30人有使用docetaxel。其中erlotinib較常使用於第二線的治療 (27
人，65.9%)，pemetrexed 較常用於第三線治療 (21 人，60%)，docetaxel 常常用於第四線
的治療 (14 人，46.7%)(當比較不同的治療藥物時，p 值皆小於 0.01)。這三種藥物的腫瘤
反應率並無顯著之差異  (erlotinib (19.5%)，pemetrexed (17.1%)，docetaxel (6.7%)，
p=0.301)。這些藥物使用在第二線或更後線治療的無疾病進展存活時間中位數有顯著之差
異(erlotinib (10.9 週)，pemetrexed (13.3 週)，docetaxel (8.3 週)，p=0.0261)。這些藥物使用
於較前線或較後線之挽救性治療的無疾病進展存活時間並無顯著之差異。所以野生型上
皮細胞生長因素接收器之肺腺癌患者於第一線化學治療失敗之後，不論使用 erlotinib，
pemetrexed，或 docetaxel，皆為有效之挽救性治療。 
 
關鍵字: 腺癌，docetaxel，erlotinib，非小細胞肺癌，pemetrexed 
 
INTRODUCTION 
Lung cancer is a significant cause of cancer death 
throughout the world, and non-small-cell lung cancer 
(NSCLC) accounts for 85% of all lung cancer cases. 
Adenocarcinoma and squamous cell carcinoma (SCC) 
are 2 major histological subtypes of NSCLC. For pa-
tients with metastatic NSCLC, chemotherapy was 
considered the standard treatment before the era of 
targeted therapy. Third-generation anti-cancer drugs in 
combination with platinum have shown better re-
sponse rates and survival than conventional regimens 
during the last 2 decades. This kind of doublet treat-
ment was used as standard first-line treatment for 
treatment-naïve advanced NSCLC before the publica-
tion of the phase III randomized trial of first-line 
therapy with gefitinib or paclitaxel plus carboplatin in 
Asians who had never smoked or who were light- 
smokers with pulmonary adenocarcinoma in 2009 [1- 
4]. Since chemotherapy is relatively nonspecific and 
toxic in nature, and improvement in survival has 
proven only modest, and new therapeutic strategies 
are needed. 
Targeted therapy against NSCLC, especially non- 
squamous NSCLC or adenocarcinoma, has produced 
marked achievements. Treatment with EGFR-tyrosine 
kinase inhibitor (TKI) (either gefitinib or erlotinib) for 
patients with tumor epidermal growth factor receptor 
(EGFR)-activating mutations has resulted in im-
provement in patient survival and a better quality of 
life [4-9]. This improvement in progression-free sur-
vival (PFS), better quality of life, and fewer treat-
ment-induced toxicities as compared to doublet chem-
otherapy were noted in patients with EGFR-activating 
mutation when EGFR-TKI was used in first-line 
treatment [4,6-9]. Thus, first-line treatment with erlo-
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tinib or gefitinib, and potentially also afatinib, is rec-
ommended for patients with tumor EGFR-activating 
mutations [10-12], while cytotoxic chemotherapy is 
preferred as first-line treatment when the tumor EGFR 
mutation status is wild-type or unknown. 
When patients had unknown or wild-type EGFR 
and also had disease progression after first-line chem-
otherapy, the options for second-line treatment in-
cluded single agent treatment with docetaxel, 
pemetrexed, or erlotinib [13-16]. Three phase III ran-
domized studies were conducted, including 2 studies 
of docetaxel that showed improved survival for 
NSCLC patients who received docetaxel as second- 
line therapy compared to the best supportive care or 
other chemotherapy [16,17], and one study of 
pemetrexed that showed pemetrexed treatment had 
advantages in terms of tolerability and quality of life 
compared to docetaxel treatment [13]. For tumor 
EGFR-unelected patients, erlotinib was also docu-
mented to be an effective agent for prolonging patient 
survival and improving quality of life compared to 
placebo treatment [15]. Thus, erlotinib, docetaxel, or  
Table 1. Patient characteristics of 41 EGFR wild-type pulmonary adenocarcinoma patients who received 
erlotinib, and pemetrexed or docetaxel as second-line or later treatment 
Characteristics Patient number (%) 
Male/Female 21/20 (51.2/48.8) 
Mean age (range) 60 (28-87) 
Smoking history yes/no* 15/26 (36.6/63.4) 
Performance status#  
    0 
    1 
    2 
    3 
 
6 (14.6) 
30 (73.2) 
4 (9.8) 
1 (2.4) 
Present treatment with erlotinib as (n=41) 
    2nd line 
    3rd line 
    4th line 
    7th line 
 
27 (65.9) 
10 (24.4) 
3 (7.3) 
1 (2.4) 
Present treatment with pemetrexed as (n=35) 
    2nd line 
    3rd line 
    4th line 
    6th line 
 
8 (22.9) 
21 (60) 
5 (14.3) 
1 (2.9) 
Present treatment with docetaxel as (n=30) 
    2nd line 
    3rd line 
    4th line 
    5th line 
 
4 (13.3) 
10 (33.3) 
14 (46.7) 
2 (6.7) 
*No smoking history is defined as never a smoker or patients who had smoked less than 100 cigarettes in their lifetime; 
#Performance status when starting erlotinib treatment 
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Figure 1. PFS of 41 EGFR wild-type pulmonary adenocarcinoma patients who received 
erlotinib treatment. Among them, 35 patients also received pemetrexed treat-
ment as salvage therapy and 30 also received docetaxel salvage therapy. The 
median PFS was 10.9 weeks, 13.3 weeks, and 8.3 weeks, respectively, for er-
lotinib, pemetrexed, and docetaxel treatment (p = 0.0261) 
 
 
pemetrexed can be used as standard second-line 
chemotherapy when patients have disease progression 
after first-line platinum-based chemotherapy. 
In the present study, we retrospectively reviewed 
our patients’ data to determine which agent was the 
better choice for tumor EGFR wild-type pulmonary 
adenocarconoma patients who had disease progression 
after first-line platinum-based chemotherapy in the 
targeted therapy era.  
 
METHODS 
This retrospective review was approved by our in-
stitutional review board (VGHIRB 2011-04-0151A). 
We retrospectively reviewed the chart records and 
case reports of our patients with metastatic adenocar-
cinoma of the lungs who were tumor EGFR wild-type 
and had disease progression after first-line plati-
num-based chemotherapy. The study patients also re-
ceived treatment with erlotinib (150 mg daily until 
disease progression) and pemetrexed (500 mg/m2 
every 3 weeks until disease progression) or docetaxel 
(60 mg/m2 every 3 weeks until disease progression) in 
our department from July 2009 to June 2012. The use 
of pemetrexed and docetaxel could have either pre-
ceded erlotinib treatment or been used after the patient 
had disease progression from erlotinib treatment. All 
patients received standard pre-medications for their 
chemotherapy. Additionally, all patients had a WHO  
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Figure 2. Differences in PFS of individual patients who received salvage treatment. Panel A shows the difference 
in PFS between erlotinib and docetaxel in individual patients. Panel B shows the difference in PFS be-
tween erlotinib and pemetrexed in individual patients 
 
 
performance status (PS) of 0 to 2 when starting these 
treatments, except for one patient who had a PS of 3 
when starting erlotinib treatment.  
All patients had documented EGFR wild-type tu-
mor. Tumor EGFR mutation status was evaluated with 
nucleotide sequence analysis. The VarientSEQr Rese-
quencing Primer Set was selected for mutational anal-
ysis of the tyrosine kinase domain and exons 18 to 21 
of the EGFR gene. Genomic DNA was extracted from 
paraffin blocks, exons 18 to 21 were amplified, and 
uncloned polymerase chain reaction fragments were 
sequenced and analyzed in both sense and antisense 
directions for the presence of heterozygous mutations. 
Normal control DNA provided by the ABI Company 
was used for wild-type control.  
The clinical characteristics, response rate, PFS of 
each treatment, and overall survival time from the 
beginning of erlotinib treatment were recorded and 
analyzed. Types of response were assessed with the 
use of the Response Evaluation Criteria in Solid Tu-
mors version 1.1. Response rate, PFS, and overall sur-
vival time were analyzed with an intention-to-treat 
principle. PFS time and overall survival time were 
analyzed using the Kaplan-Meier estimation method 
and log-rank test. PFS was calculated from the date of 
initiation of treatment to the date of disease progres-
sion or death from any cause. If disease progression 
had not occurred by the time of this analysis, PFS was 
considered to have been censored at the time of the 
last follow-up visit. Survival time was measured from 
the date of the initiation of erlotinib treatment to the 
date of death. Survival time was considered to have 
been censored at the last follow-up if death had not 
occurred. The comparisons of clinical characteristics 
and response rates were performed using the χ2 analy-
sis. The difference in lines of treatment between dif-
ferent agents were compared using the Mann-Whitney 
test. SPSS (Statistical Package for the Social Sciences) 
statistical software was used (SPSS Inc., Chicago, IL, 
USA). 
 
RESULTS 
Forty-one patients with EGFR wild-type, stage 
IV pulmonary adenocarcinoma, who had disease 
progression from first-line platinum-based chemo-
therapy and then had been treated or were under 
treatment with erlotinib and pemetrexed or docetaxel 
were included during this period. All 41 patients re-
A B
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ceived erlotinib treatment; 35 of the 41 patients also 
received pemetrexed treatment and 30 of the 41 pa-
tients also received docetaxel treatment during their 
disease course. The clinical characteristics of these 
patients are listed in Table 1. There was a significant 
difference in treatment lines between erlotinib and 
pemetrexed (p = 0.001), erlotinib and docetaxel (p < 
0.001), and pemetrexed and docetaxel ( p = 0.009).  
Of the patients with a response to erlotinib treat-
ment (n = 41), 8 (19.5%) had a partial response, 12 
(29.3%) had stable disease, and 21 (51.2%) had pro-
gressive disease. There was a partial response to 
pemetrexed treatment (n = 35) in 6 patients (17.1%), 
stable disease in 12 (34.3%), and progressive disease 
in 17 (48.6%). For docetaxel treatment (n = 30), there 
was a partial response in 2 patients (6.7%), stable dis-
ease in 7 (23.3%), and progressive disease in 21 
(70%). There was no significant difference in response 
to treatment or not between the different treatment 
agents (p = 0.301). The response rate when patients 
received erlotinib, pemetrexed, and docetaxel as se-
cond-line therapy was 25.9% (7 of 27 cases), 12.5 % 
(1 of 8 cases), and 0% (0 of 4 cases). The disease con-
trol rate was 48.8%, 51.4% and 30% for erlotinib, 
pemetrexed, and docetaxel, respectively. There was 
also no correlation of treatment response between the 
different agents (p = 0.763 for erlotinib and 
pemetrexed, 0.102 for erlotinib and docetaxel, and 
0.414 for pemetrexed and docetaxel).  
The median PFS of the 41 patients who received 
erlotinib treatment was 10.9 weeks (censor 2, 95% CI, 
3-18.7 weeks), and 15.3 weeks and 8.9 weeks, respec-
tively, for second- and ≥ third-line erlotinib treatment 
(p = 0.9449). The median PFS of the 35 patients who 
received pemetrexed treatment was 13.3 weeks (cen-
sor 2, 95% CI, 6-22.9 weeks), and 14.9 weeks and 8.3 
weeks, respectively, for second- or third- and ≥ 
fourth-line pemetrexed treatment (p = 0.9449). The 
median PFS of the 30 patients who received docetaxel 
treatment was 8.3 weeks (censor 1, 95% CI, 5.4-11.1 
weeks), and 9.7 weeks and 7.1 weeks, respectively, for 
second- or third- and ≥ fourth-line docetaxel treatment 
(p = 0.9449). The median PFS of patients received 
pemetrexed and docetaxel as second-line therapy was 
9.6 weeks and 7.1 weeks, respectively. However, there 
was a significant difference in PFS between docetaxel 
and the other agents (p = 0.0261, Figure 1). The ma-
jority of patients had longer PFS when receiving erlo-
tinib than when receiving docetaxel treatment, which 
differed from pemetrexed treatment, with about half of 
the patients responding well (Figure 2). 
The median survival was 123 weeks (95% CI, 
76.1-169.9 weeks) after starting erlotinib treatment. 
However, this data is still preliminary, with 23 (56.1%) 
censored.  
 
DISCUSSION 
EGFR-TKIs, either erlotinib or gefitinib, have 
been documented to be effective agents in the treat-
ment of EGFR-mutated NSCLC. In addition, erlotinib 
was documented to prolong survival in a phase III 
randomized study of EGFR-unselected NSCLC pa-
tients, compared to placebo treatment [15]. Erlotinib 
was found to be more effective than gefitinib in a 
multi-center retrospective review of Taiwanese tumor 
EGFR-unselected NSCLC patients [18]. Furthermore, 
erlotinib maintenance therapy also showed this treat-
ment is effective in prolonging patients’ PFS and 
overall survival, even in patients with tumor EGFR 
wild-type NSCLC [19]. The underlying mechanism 
might be the sensitivity to erlotinib treatment of some 
EGFR wild-type NSCLC cells, according to in vitro 
IC50 studies of NSCLC cell lines [20-23]. With the 
more frequent usage of EGFR-TKIs as second-line 
treatment for EGFR wild-type NSCLC, due to their 
relative convenience of use and better toxicity profiles, 
docetaxel and pemetrexed, which were used previ-
ously as second-line chemotherapeutic agents, will 
likely be repositioned as third-line or even fourth-line 
treatments [24,25]. 
The available data from clinical trials performed in 
the last decade are not sufficient to make a recom-
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mendation for or against using a cytotoxic drug as 
third-line treatment against pulmonary adenocarcino-
ma or NSCLC, not to mention fourth-line treatment. 
Almost all the large phase III randomized trials of 
second-line salvage therapy for NSCLC or adenocar-
cinoma that were published either in full or abstract 
form involved EGFR-unselected patients, except an 
abstract that was published recently at the 2012 annual 
meeting of the American Society of Clinical Oncology 
[26]. This phase III randomized trial comparing erlo-
tinib with docetaxel in the second-line treatment of 
tumor EGFR wild-type NSCLC patients reported that 
PFS and response rate were significantly better in the 
docetaxel arm than in the erlotinib arm [26].  
Our previous phase II trial included 161 
EGFR-unselected NSCLC patients who were ran-
domized to receive 3 different schedules of docetaxel 
treatment [27]. More than 90% of patients received 
docetaxel as second-line therapy. The objective re-
sponse rates were 17.2% for the 4-weekly schedule, 
10.9% for the 3-weekly schedule, and 6.1% for the 
standard every 3 weeks schedule (p = 0.615). The me-
dian PFS was 4.2 months in the 4-weekly schedule, 
3.5 months in the 3-weekly schedule, and 2.8 months 
in the standard every 3 weeks schedule (p = 0.271). 
Another phase II randomized trial of pemetrexed 
4-cycle treatment followed by docetaxel 4-cycle 
treatment (pemetrexed in the first arm), or a reversed 
sequence (docetaxel in the first arm), included 118 
EGFR-unselected NSCLC patients, with 59 patients in 
each arm [24]. Objective response rates for the first 
agent were 22.4% in the pemetrexed-first arm and 
5.2% in the docetaxel-first arm (p = 0.007). Median 
PFS was 4 months in the pemetrexed-first arm and 3.8 
months in the docetaxel-first arm (p = 0.4357) [24]. 
The response rates in these 2 randomized studies were 
consistent with those of the present retrospective study: 
17.1% with pemetrexed treatment and 6.7% with 
docetaxel treatment. The shorter PFS with docetaxel 
treatment in the present study was probably due to its 
use as later-line treatment compared to the 2 other 
drugs. However, this difference in PFS noted between 
docetaxel and the other agents cannot be sufficiently 
explained by its use as a later line of treatment than 
the other 2 agents, because no significant difference in 
PFS was found for each individual agent when used in 
an earlier or later line of salvage therapy, although a 
numerically shorter PFS was found for all 3 drugs. 
The PFS of the 3 drugs in the present study was 
still within a reasonable range compared to our previ-
ous studies [24,25,27]. The erlotinib response rate was 
higher in the present study due to the detection of the 
EGFR mutation status using the DNA sequencing 
method. The sensitivity of direct sequencing is rela-
tively poor and could induce a false negative result. 
Thus, a 10%-20% objective response rate, sometimes 
even higher in specific clinical subpopulations, was 
noted in EGFR wild-type NSCLC patients with EGFR 
mutation analysis performed by the DNA sequencing 
method [28,29].    
In this study, the first-line chemotherapy included 
pemetrexed. Therefore, the benefit of pemetrexed as it 
affects overall survival might be confounded because 
of crossover. However, crossover of pemetrexed is 
necessary because it would be unethical to limit the 
use of pemetrexed in eligible patients. 
In conclusion, the present study showed that erlo-
tinib, pemetrexed, and docetaxel were all effective 
salvage therapy agents for EGFR wild-type adenocar-
cinoma patients.  
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